- Prev close
- $676.04
- Day range
- $650.00 – $680.57
- From 52-wk high
- -12.2%
IDXX had a sharp re-rating on an earnings-preview setup, but the move is larger than the broad market’s -1.8% S&P 500 and -3.5% Nasdaq decline and comes after a run to $671.64, so the gap looks event-driven rather than clearly fundamental.
IDXX
IDEXX LABORATORIES INC
As of Nov 2, 2026
66/100
Worth keeping an eye onHealth ScoreWhy it moved
The stock’s +21.8% move is far larger than the S&P 500’s -1.8% and the Nasdaq 100’s -3.5%, so the primary driver is stock-specific rather than the market. There is no fresh company announcement in the facts; the clearest catalyst is the earnings-window setup, with the recent note that IDXX is "Reports Next Week: Wall Street Expects Earnings Growth."
Volatility check
This is not ordinary day-to-day volatility for a mature healthcare name: the shares moved +21.8% with beta at 1.55, against revenue growth of +12.8% YoY (TTM), latest-quarter growth of +9.7% YoY, and EPS growth of +18.4% YoY (TTM). The quality of the business is strong, with gross margin +62.5%, operating margin +32.0%, and net margin +25.0%, but the valuation is already rich at PE 44.4, forward PE 33.5, and PEG 2.83 — a PEG of 2.83 means the stock is valued at 2.83 times its growth rate, so strong growth is already priced in and the share price can swing hard on earnings expectations.
Earnings preview
The next earnings date is not provided this period, but the facts say IDXX is "Reports Next Week" and that Wall Street expects earnings growth. The consensus backdrop available here is the company’s own operating profile: revenue +12.8% YoY (TTM), latest-quarter revenue +9.7% YoY, EPS +18.4% YoY (TTM), with gross margin +62.5%, operating margin +32.0%, and net margin +25.0%. The market will be focused on whether growth stays near the +9.7% latest-quarter pace, whether margins hold near +32.0% operating margin, and whether management confirms that the earnings beat setup implied by the recent note is intact. Prior post-earnings reaction data are not available in the facts.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track IDXX with WhyIHold
Get a plain-English explanation the next time IDEXX LABORATORIES INC makes a big move — so you know whether it's benign or worth your attention.